Stifel downgraded Avantor (AVTR) to Hold from Buy with a price target of $14, down from $26. The company missed Q1 estimates and lowered the sales organic growth guidance by 200 basis points, but the totality of the results and earnings call were worse than that, the analyst tells investors in a research note. The firm says growth in bioprocess is lagging, tariff impacts do not appear fully baked-in, pricing improvement strategies that will be critical to managing the trade war are still being optimized, and Avantor appears to be losing share. Stifel believes there are too many other high-quality tools names trading at discounted multiples to favor this one right now.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR:
